Detalhe da pesquisa
1.
Safety and immunogenicity of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120 vaccine boost adjuvanted with MF59 or alum in healthy adults without HIV (HVTN 107): A phase 1/2a randomized trial.
PLoS Med
; 21(3): e1004360, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38502656
2.
Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial.
Lancet HIV
; 5(7): e366-e378, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29898870